A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

Overview

1. A maximally tolerated dose of ribavirin can be defined in each patient with ESRD undergoing hemodialysis. 2. Patients with Chronic Hepatitis C Virus (HCV)and End-Stage Renal Disease (ESRD)undergoing hemodialysis will be able to tolerate and remain on treatment with peginterferon alfa-2b, the maximally tolerated dose of ribavirin and boceprevir. 3. A significant percentage of patients with chronic HCV and ESRD undergoing hemodialysis can achieve rapid virologic response (RVR), extended virologic response (eRVR) and sustained virologic response (SVR) when treated with peginterferon alfa-2b, the maximally tolerated dose of ribavirin and boceprevir.

Full Title of Study: “A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2014

Detailed Description

Patients with ESRD will be treated with a dose escalation of ribavirin starting from 200 mg everyday (QD) to a maximal tolerated dose. Peginterferon will then be added. Ribavirin will be dose adjusted as needed. Boceprevir will then be added. Ribavirin will be dose adjusted as needed. Patients will be monitored for eRVR and SVR. The study end-point is eRVR.

Interventions

  • Drug: Ribavirin
    • Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
  • Drug: Peginterferon
    • After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
  • Drug: Boceprevir
    • Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.

Arms, Groups and Cohorts

  • Experimental: Ribavirin, peginterferon, boceprevir
    • The efficacy and safety of HCV treatment in patients with ESRD will be assessed with a maximal tolerated dose of ribavirin, peginterferon and boceprevir.

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of patients who achieve eRVR at treatment week 28
    • Time Frame: 28 weeks
    • The primary end-point for evaluation will be the percentage of patients who achieve eRVR at treatment week 28.

Secondary Measures

  • Tolerability of treatment
    • Time Frame: 48 weeks
    • A. The ability to define the maximal tolerated dose of ribavirin. B. The ability to remain on peg-interferon alfa-2b, ribavirin and boceprevir for 24 weeks C. The percentage of patients who achieve SVR

Participating in This Clinical Trial

Inclusion Criteria

  • Chronic HCV defined by: – A history of a positive anti-HCV or HCV RNA for > 6 months or – A liver biopsy demonstrating at least portal fibrosis – HCV genotype 1 – No prior treatment with any interferon or peginterferon preparation – ESRD undergoing hemodialysis for at least 6 months – Willingness not to conceive a child during treatment and for 6 months following discontinuation of treatment. Exclusion Criteria:

  • Histologic evidence of cirrhosis – Any co-existent liver disease – A platelet count < 90,000 – A total white blood cell (WBC) < 2.5 – An absolute neutrophil count < 1.5 – Hemoglobin < 11 gm/dl on Epoetin-alpha – Positive test for anti-HIV – Pregnancy of the patient or their intimate partner – Women who are breast feeding – Significant cardiovascular disease – History of suicide intent, severe depression requiring hospitalization or significant psychiatric disease – Malignancy within 5 years of enrollment except for squamous or basal cell skin cancer – Co-existent immune disorder such as lupus, rheumatoid as arthritis, colitis, Crohns disease, sarcoidosis, etc. – Any patient in the opinion of the investigator who would not be a satisfactory study candidate

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Liver Institute of Virginia
  • Collaborator
    • Merck Sharp & Dohme LLC
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Mitchell L Shiffman, MD, Principal Investigator, Liver Institute of Virginia, Bon Secours Health System
  • Overall Contact(s)
    • Mitchell L Shiffman, MD, 804-977-8920, mitchell_shiffman@bshsi.org

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.